{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:28:37Z","timestamp":1791606517761,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.urology.2022.11.006","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:16:14Z","timestamp":1669295774000},"page":"56-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["National Trends in Third-Line Treatment for Overactive Bladder Among Commercially Insured Women, 2010-2019"],"prefix":"10.1016","volume":"175","author":[{"given":"Preston","family":"Edge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas F.","family":"Scioscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"Yanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria L.","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2022.11.006_bib0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2022.11.006_bib0002","first-page":"94","article-title":"Treatment of overactive bladder in women","volume":"187","author":"Hartmann","year":"2009","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"10.1016\/j.urology.2022.11.006_bib0003","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.11.006_bib0004","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/AOG.0000000000000851","article-title":"Comparative effectiveness of anticholinergic therapy for overactive bladder in women","volume":"125","author":"Reynolds","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.urology.2022.11.006_bib0005","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/AOG.0000000000003517","article-title":"Development and validation of a machine learning algorithm for predicting response to anticholinergic medications for overactive bladder syndrome","volume":"134","author":"Sheyn","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.urology.2022.11.006_bib0006","unstructured":"Premarket Approval Database: Interstim. Food and Drug Administration Web Site. Silver Spring, MD. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P970004. Accessed October 8, 2021."},{"key":"10.1016\/j.urology.2022.11.006_bib0007","unstructured":"510(k) Premarket Notification Database: NURO Neuromodulation System. Food and Drug Administration Web Site. Silver Spring, MD. Available at: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf10\/K101847.pdf. Accessed October 8, 2021."},{"key":"10.1016\/j.urology.2022.11.006_bib0008","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","article-title":"Treatment of neurogenic incontinence with botulinum toxin A","volume":"342","author":"Schurch","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2022.11.006_bib0009","unstructured":"Drug Databases: FDA-Approved Drugs: BOTOX. Food and Drug Administration Web Site. Silver Spring, MD. Available at:https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=103000. Accessed October 8, 2021."},{"key":"10.1016\/j.urology.2022.11.006_bib0010","series-title":"Databases for Pharmacoepidemiological Research","first-page":"243","article-title":"IBM MarketScan research databases","author":"Butler","year":"2021"},{"key":"10.1016\/j.urology.2022.11.006_bib0011","unstructured":"Watson Health IBM Corporation 2021. IBM MarketScan research databases for life sciences researchers. Available at: https:\/\/www.ibm.com\/products\/marketscan-research-databases\/databases. Accessed April 20, 2022."},{"key":"10.1016\/j.urology.2022.11.006_bib0012","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JU.0000000000000462","article-title":"Real world performance of sacral neuromodulation and onabotulinumtoxinA for overactive bladder: focus on safety and cost","volume":"203","author":"Chughtai","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.11.006_bib0013","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1097\/SPV.0000000000000744","article-title":"National patterns of filled prescriptions and third-line treatment utilization for privately insured women with overactive bladder","volume":"27","author":"Linder","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.urology.2022.11.006_bib0014","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/nau.23276","article-title":"Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States","volume":"37","author":"Anger","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2022.11.006_bib0015","unstructured":"Glossary. United States census bureau web site. Available at: https:\/\/www.census.gov\/programs-surveys\/metro-micro\/about\/glossary.html. Accessed August 11, 2022."},{"key":"10.1016\/j.urology.2022.11.006_bib0016","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1089\/jwh.2021.0635","article-title":"Why patients fall through the cracks: assessment of patients' overactive bladder treatment","volume":"31","author":"Davidson","year":"2022","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.urology.2022.11.006_bib0017","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JU.0000000000000569","article-title":"National trends in the surgical management of urinary incontinence among insured women, 2004 to 2013: the Urologic Diseases in America Project","volume":"203","author":"Lee","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.11.006_bib0018","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.juro.2015.03.111","article-title":"Disparities in the use of sacral neuromodulation among Medicare beneficiaries","volume":"194","author":"Laudano","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.11.006_bib0019","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.urology.2020.04.102","article-title":"Contemporary patterns of third-line treatments for privately insured individuals with overactive bladder in the United States","volume":"142","author":"Jiang","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.urology.2022.11.006_bib0020","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/jrh.12644","article-title":"Trend in rural-urban disparities in access to outpatient mental health services among US adults aged 18-64 with employer-sponsored insurance: 2005-2018","volume":"38","author":"Chen","year":"2022","journal-title":"J Rural Health"},{"key":"10.1016\/j.urology.2022.11.006_bib0021","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/1475-6773.13096","article-title":"Rural-urban disparities in health care costs and health service utilization following pediatric mild traumatic brain injury","volume":"54","author":"Graves","year":"2019","journal-title":"Health Serv Res"},{"key":"10.1016\/j.urology.2022.11.006_bib0022","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.urology.2021.09.018","article-title":"A systematic review of racial\/ethnic disparities in female pelvic floor disorders","volume":"163","author":"Gonzalez","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.urology.2022.11.006_bib0023","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/JU.0000000000001545","article-title":"The effect of social determinants of health on overactive bladder symptom severity","volume":"205","author":"Tellechea","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.11.006_bib0024","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JU.0000000000000458","article-title":"Treatment of urinary urgency incontinence using a rechargeable SNM System: 6-month results of the ARTISAN-SNM Study","volume":"203","author":"McCrery","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.11.006_bib0025","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.juro.2018.10.017","article-title":"Feasibility of a fully implanted, nickel sized and shaped tibial nerve stimulator for the treatment of overactive bladder syndrome with urgency urinary incontinence","volume":"201","author":"MacDiarmid","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.11.006_bib0026","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.urology.2022.11.006_bib0027","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Alzheimer's disease neuroimaging initiative. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429522009803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429522009803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:05:12Z","timestamp":1758769512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429522009803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"alternative-id":["S0090429522009803"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2022.11.006","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National Trends in Third-Line Treatment for Overactive Bladder Among Commercially Insured Women, 2010-2019","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2022.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}